The Trump administration's aid freeze affects HIV treatment access. Find out how organizations are coping with the directive.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

The State Department issued a waiver for lifesaving aid, but HIV clinics remain shut and uncertainty lingers over the future ...

The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via ...

PreP is extremely effective at preventing HIV infection. According to the Centers for Disease Control and Prevention, PReP drugs like Truvada Descovy can reduce the risk of getting HIV by 99 percent ...

The Supreme Court will hear a challenge to Obamacare’s preventive care mandates, giving Trump a chance to reshape rules on ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

The US government alleged that Gilead had inadequately compensated the CDC for its pivotal research on Truvada's preventative uses, supposedly sidestepping pertinent patents. With the settlement now ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a pair of HIV prevention pills.

Gilead Sciences (NASDAQ:GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and Descovy. The lawsuit stemmed from research Gilead (NASDAQ:GILD) ...